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Osteosarcoma is the most common bone cancer in children and young adults. Surgery 
and multi-agent chemotherapy are the standard treatment regimens for this disease. 
New therapies are being investigated to improve overall survival in patients. Molecular 
targets that actively modulate cell processes, such as cell-cycle control, cell proliferation, 
metabolism, and apoptosis, have been studied, but it remains a challenge to develop 
novel, effective-targeted therapies to treat this heterogeneous and complex disease. 
MicroRNAs (miRNAs) are small non-coding RNAs that play critical roles in regulating cell 
processes including growth, development, and disease. miRNAs function as oncogenes 
or tumor suppressors to regulate gene and protein expression. Several studies have 
demonstrated the involvement of miRNAs in the pathogenesis of osteosarcoma with 
the potential for development in disease diagnostics and therapeutics. In this review, we 
discuss the current knowledge on the role of miRNAs and their target genes and eval-
uate their potential use as therapeutic agents in osteosarcoma. We also summarize the 
efficacy of inhibition of oncogenic miRNAs or expression of tumor suppressor miRNAs 
in preclinical models of osteosarcoma. Recent progress on systemic delivery as well 
as current applications for miRNAs as therapeutic agents has seen the advancement 
of miR-34a in clinical trials for adult patients with non-resectable primary liver cancer 
or metastatic cancer with liver involvement. We suggest a global approach to the 
understanding of the pathogenesis of osteosarcoma may identify candidate miRNAs as 
promising biomarkers for this rare disease.
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introduction
Osteosarcoma (OS) is an aggressive bone cancer that affects children and adolescents. Approximately 
60% of cases are pediatric patients between 10 and 20 years of age (1). Several studies suggest that 
OS arises from primitive mesenchymal bone-forming cells that undergo aberrant alterations in the 
differentiation program. This results in a heterogenic cancer, with complex etiology, characterized 
by vast genomic instability, highly abnormal karyotypes, and multiple genomic aberrations with 
copy number gains and losses occurring at multiple chromosomes (2, 3). Patients with certain rare 
and inherited syndromes, such as Li–Fraumeni syndrome, hereditary retinoblastoma, Rothmund–
Thomson syndrome, Bloom syndrome, and Werner syndrome have a higher incidence of OS (4). 
Treatment involves standard chemotherapy administered before and after surgery, and may be 
followed by radiation, which achieves a 5-year survival rate of 60–70% of patients. However, the 
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survival of patients with locally advanced or metastatic tumors 
at diagnosis, and recurrent disease remains low (~20%), and the 
median survival time for these patients is only 23  months (5). 
Current clinical trials of cytotoxic chemotherapy and targeted 
agents may achieve an objective response in a subset of patients 
with OS, but have not increased overall survival in the recent 
treatment era. Further, constitutive and acquired resistance to 
these therapies remains a clinical challenge. Therefore, a global 
understanding of the underlying factors of tumor biology will 
assist in the identification of diagnostic and prognostic markers 
and therapeutic targets for the management of patients with OS.
MicroRNAs (miRNAs) belong to the group of small, non-
coding, regulatory RNA molecules, ranging between 18 and 
25 nucleotides in length (6). They recognize and bind specific 
target mRNAs by complete or partial base-pairing mostly at 
the 3′-untranslated region (UTR) of the target genes to post-
transcriptionally regulate gene expression. Since their discovery 
nearly 20  years ago, bioinformatics and biological studies 
have identified >1,000 miRNAs that regulate possibly 50% of 
human genes. Each miRNA likely controls hundreds of gene 
transcripts (7). The sequences of miRNAs are highly conserved 
among distantly related organisms, indicating their participation 
in essential biological processes as development, cellular differen-
tiation, metabolism, proliferation, and apoptosis. Moreover, they 
regulate biological systems as stemness, immunity, and cancer. 
Studies show that more than 50% of miRNA genes are located at 
fragile chromosomal sites and in proximity to regions of deletion 
or amplification that are altered in human cancer, implicating a 
direct involvement for miRNAs in tumorigenesis (8). Families 
of miRNAs that share similar “seed” sequences or are located in 
close proximity on a single genomic locus may be co-expressed 
to form miRNA regulatory networks in particular physiological 
or pathological contexts. miRNAs that are underexpressed in 
cancers are tumor suppressors (loss of miRNA contributes to the 
malignant phenotype), while highly expressed miRNAs function 
as oncogenes (gain of miRNA contributes to the malignant phe-
notype). These expression changes control many genes involved 
in cell proliferation or apoptosis. Therefore, expression profiles 
of miRNAs may be applied as biomarkers for cancer diagnosis.
The first study on miRNA expression in OS, published by Gao 
et al. (9), identified 182 miRNAs from a human OS cell line, indi-
cating that miRNAs may contribute to the pathogenesis of OS. 
Recently, whole genome analysis of DNA copy number, mRNA 
gene expression, and miRNA transcript profiling performed in 
seven OS patient tumors identified a signature of 38 differentially 
expressed miRNAs in OS tumors compared to normal osteoblasts 
(10). Of these, expression levels of 28 miRNAs were down-
regulated and 10 were upregulated ≥10-fold in tumors versus 
osteoblasts, providing likely candidates for further investigation. 
Other miRNA profiling studies have shown altered expression 
of several distinct miRNAs in OS tumors including miR-135b, 
miR-150, miR-542-5p, and miR-652 that were validated in a 
separate group of tumors (11). The analysis of common insertion 
site (CIS)-associated genes identified three miRNAs (miR-181, 
miR-17-5p, and miR-26a-5p) as significant upstream regula-
tors in human OS (12). Also, aberrant expression of individual 
miRNAs is well-recognized to play a role in the initiation and 
progression of various cancers. The oncogenic miR-17–92 cluster 
is overexpressed in several types of cancer and promotes cell 
proliferation (13). In contrast, downregulation of the miR-15/16 
family increases expression of anti-apoptotic proteins B-cell 
lymphoma 2 (Bcl-2) and myeloid leukemia cell differentiation 
protein (Mcl-1) (14) and loss of let-7a facilitates amplification 
of the c-myelocytomatosis virus (MYC) oncogene to promote 
B-cell tumorigenesis (15). Characterization of these miRNAs that 
display altered expression in OS may provide distinct miRNAs 
or miRNA signatures related to particular molecular patterns 
associated with this disease.
Unlike many other types of cancer, there are no traditional 
biomarkers for OS. The presence of metastatic disease and his-
tologic response assessed following adjuvant chemotherapy (i.e., 
the extent of necrosis) are the only generally accepted predictors 
of event-free survival (16). The identification of new diagnostic 
miRNA biomarkers has the potential to complement existing risk 
prediction models and could eventually have a prognostic value 
in this disease. miRNA expression signatures are undergoing 
clinical investigation in pediatric patients with central nervous 
system (CNS) tumors (NCT01595126, NCT01556178), CNS 
tumors along with leukemia and lymphoma (NCT01541800), 
acute myeloid leukemia (AML) (NCT01229124), and neurofi-
bromatosis Type 1 (NF-1) (NCT01595139). Also, the molecular 
analysis of solid tumors (MAST) clinical trial (NCT01050296) 
is designed to prospectively characterize the molecular, cellular, 
and genetic properties of primary and metastatic solid tumors in 
patients including OS. These studies present a novel opportunity 
to investigate the expression of miRNAs in the blood, body fluids, 
and tissue of patients as an early predictor of cancer as well as a 
marker of response to therapy. Of note, one Phase 1 clinical trial 
conducted by MiRNA Therapeutics Inc. is evaluating miR-34 as 
an miRNA replacement therapy in patients with non-resectable 
primary liver cancer, with liver metastasis from other cancers, 
and a cohort of patients with hematological malignancies 
(NCT01829971).
The various genomic and molecular alterations, which are 
linked to the development and progression of OS are well estab-
lished. These include germline mutations, gene amplifications 
and deletions, overexpression and activation of receptor tyrosine 
kinases (RTKs), enhanced cell proliferation, resistance to apoptosis, 
metastasis, drug resistance genes, and miRNAs [reviewed in Ref. 
(17); and available at http://osteosarcoma-db.uni-muenster.de]. 
These alterations mediate changes that affect the expression and 
function of several genes and gene regulatory networks. miRNA 
profiling and computational analyses have identified associations 
between miRNAs and many gene and gene products linked to 
these aberrant factors. This review discusses some of the promi-
nent pathological factors of OS that may be regulated by miRNAs 
and highlights miRNAs that are validated in preclinical OS models.
miRNAs in the Pathogenesis of OS
Germline Mutations
Osteosarcoma is characterized by complex, unbalanced karyo-
types, and the pattern of abnormalities varies among patients. 
Numerical and structural chromosome abnormalities are 
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detected in the majority of OS tumors (58%) (3, 17–19). Common 
numerical chromosomal abnormalities are polyploidy, caused 
by errors in mitosis, aneuploidy, germline mutations, deletions, 
duplications, and unbalanced translocations. These include gain 
of chromosome 1, loss of chromosomes 9, 10, 13, and/or 17, 
partial or complete loss of the long arm of chromosome 6 and 
ring chromosomes (7%) (19, 20). Characteristic reciprocal trans-
locations are absent in OS and rearrangements of chromosomes 
11, 19, and 20 are frequent structural abnormalities (21). Two 
of the most prominent genes that harbor germline mutations 
are the retinoblastoma tumor suppressor gene (RB1) and the 
TP53 tumor suppressor gene (2). These genes are important for 
mitotic checkpoints and are thought to be the underlying cause of 
chromosomal instabilities. Most OS tumors contain inactivation 
of both the retinoblastoma (Rb) and p53 pathways.
RB1
The retinoblastoma protein (pRb) was the first described tumor 
suppressor. pRb1 is a checkpoint protein that binds the E2F fam-
ily of transcription factors and inhibits cell-cycle progression. 
The activation of cyclin-dependent kinases (CDK) and cyclins 
by mitogenic signals phosphorylates pRb, which dissociates from 
E2F transcription factors. This leads to the activation of E2F tar-
get genes to facilitate the G1/S transition and S-phase progression 
(22). Thus, loss of function of the RB1 gene drives tumorigen-
esis in many adult and pediatric cancers including OS (23, 24), 
retinoblastoma (25), medulloblastoma, supratentorial primitive 
neuroectodermal tumor (sPNET) (26), and acute lymphoblastic 
leukemia (ALL) (27). Gene mutations occur in 20–40% of patients 
with sporadic OS (28) and loss of heterozygosity (LOH) at 13q, 
the site of location of the RB1 gene occurs in approximately 70% 
of OS cases (29). Germline mutations along with genetic loss or 
deletions of RB1 are associated with inactivation of pRb. These are 
considered as high risk factors for the development of OS and are 
linked to poor outcome (29).
An miRNA signature consisting of miR-9-5p, miR-138, 
and miR-214 was predicted to target mRNA genes that encode 
proteins involved in pRb-signaling in OS (30). However, the 
experimental validation of these miRNA:mRNA interactions 
has not been conducted. Other miRNAs including miR-449a, 
miR-449b, and the miR-17–92 locus have been described in 
the regulation of Rb/E2F (E2F transcription factor) pathway in 
many cancers (31). Mechanistically, miR-449a and miR-449b 
were direct transcriptional targets of the E2F transcription factor 
1 (E2F1) and negative modulators of pRb phosphorylation by 
inhibition of (cyclin-dependent kinase 6) CDK6 and cell division 
cycle 25A (CDC25A) (32). This was consistent with the previ-
ously identified regulation of CDK/pRb/E2F1 through an auto-
regulatory feedback mechanism by miR-449a (33). Interestingly, 
miR-449a was expressed in low levels in OS cell lines and tumors 
and directly targeted the binding site within the 3′-UTR of the 
BCL2 mRNA (34). In a separate study, restoration of miR-29a in 
osteoblastic cells using miRNA mimetics was shown to repress 
BCL2 mRNA and induce E2F3 and its transcriptional target, 
E2F1 (35). Collectively, these findings support a pro-apoptotic 
and tumor suppressor role for miR-29a that may participate with 
miR-449 to regulate the Rb/E2F signaling network in OS.
miR-17–92 is a well-studied polycistronic miRNA cluster in 
cancer. The miR-17–92 locus contains 15 miRNAs that form four 
“seed” families, miR-17, miR-18, miR-19, and miR-92. Many of 
these are reported to be amplified in diffuse B-cell lymphoma, 
lung, breast, and pancreatic cancers, as well as OS (13, 36, 37). 
Direct target genes of miR-17–92 include E2F1, phosphatase and 
tensin homolog (PTEN), and p21 (13). Two members of the miR-
17–92 cluster (miR-17-5p and miR-18a) were among five highly 
expressed oncogenic miRNAs in several OS cell lines that were 
suggested to be predictive of poor disease prognosis (36). In the 
Sleeping Beauty (SB) transposon-based forward genetic screen, 
miR-17-5p was one of the three enriched upstream regulators 
identified in an OS mouse model (12). Future studies to establish 
the function of miR-17–92 in OS are warranted.
TP53
The human p53 gene encodes the p53 tumor suppressor protein 
that plays a crucial role in maintaining genomic stability. The 
p53 tumor suppressor functions as a transcription factor that 
regulates the expression of various genes that are involved in cell-
cycle arrest, DNA repair, and apoptosis. In normal, unstressed 
cells, mouse double minute 2 (MDM2) binds and inhibits p53 
function to allow p53 degradation via the ubiquitin/proteasome 
pathway. In stressed cells, p53 is stabilized, and p53 transcrip-
tional activity is promoted. Alterations in the TP53 gene are 
associated with functional inactivation of p53 and less favorable 
prognosis in OS (38). Genetic abnormalities of p53, such as 
allelic loss (75–80%), gene rearrangements (10–20%), or point 
mutations (20–30%) are reported in 50% of OS patients (39). The 
MDM gene is also amplified in 16% of OS patients and is associ-
ated with aggressive disease (40). Patients with the Li–Fraumeni 
syndrome with a germline mutation of TP53 are predisposed to 
developing OS.
Studies involving various cancer types have validated several 
miRNAs that are components of the signaling cascades that regu-
late p53 expression. miR-125b, miR-504, miR-25, and miR-30d are 
reported to directly bind the p53 mRNA and negatively regulate 
p53 expression (41). In addition, miR-34a, miR-192, miR-194, 
miR-215, miR-605, and miR-29 regulate upstream components 
and indirectly activate p53 (41). Of these, miR-34a is a key tumor 
suppressor that regulates numerous genes that are involved in 
DNA damage and repair. A positive feedback loop mediated by p53 
target sites in the miR-34a promoter also controls transactivation 
of miR-34a by p53 (42, 43). Mutations in TP53, functional inhibi-
tion of p53, and hypermethylation of the miR-34a promoter are 
all associated with the loss of miR-34a expression in tumors (44). 
In a p53-expressing OS cell line, DNA damage-induced miR-34a 
expression was dependent on p53, which in turn led to the induc-
tion of cell-cycle arrest, promotion of apoptosis, and DNA repair 
(45). This was not observed with p53-deficient OS cells, illustrat-
ing that miR-34a was a downstream target of p53. Restoration 
of miR-34a with miRNA mimics in OS cells repressed p53 and 
runt-related transcription factor 2 (RUNX2) and suppressed 
tumor cell growth (46). Notably, miR-34a was demonstrated to 
be a target of C/EBPα CCAAT/enhancer-binding protein-alpha 
(C/EBPα, encoded by the gene CEBPA) during granulopoiesis, 
and low expression in leukemic blasts with CEBPA mutations 
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elevated levels of E2F3 and its transcriptional target, E2F1 (47). 
A clinical study of the role of miR-34a and miR-194 in pediatric 
patients with AML with mutated CEBPA was recently concluded 
by the Children’s Oncology Group and the results of this study are 
pending (NCT01057199).
p53 can transcriptionally induce miR-192 and miR-215 in 
several types of cancer (48). These miRNAs were markedly 
downregulated in OS (49), and transactivation of miR-192 and 
miR-215 by p53 was also reported in OS cell lines (48). The 
ratio of expression levels of miR-192 and miR-215 has been 
proposed to differentiate p53-negative and p53-expressing OS 
patient tumors (49). In addition, miR-215 has been implicated in 
p53-mediated chemoresistance to methotrexate and the thymi-
daylate synthase inhibitor, Tomudex, in OS cell lines. Resistance 
was mediated through repression of the denticleless protein 
homolog (DTL), a cell-cycle-regulated nuclear, and centrosome 
protein (50). Together, these findings support miR-34a, miR-192, 
and miR-215 as candidates for novel biomarkers of prognosis and 
drug response in OS.
Gene Amplifications
Several genetic deletions and amplification are considered pre-
disposing conditions to OS. Genomic amplifications (homogene-
ously staining regions) occur in approximately 30% of OS cases 
(20), which are associated with the action of oncogenes, such as 
apurinic/apyrimidinic exonuclease 1 (APEX1), cellular homolog 
of avian MYC, RecQ protein-like 4 (RECQL4), CDK4, MDM2, 
RUNX2, and vascular endothelial growth factor A (VEGFA) (51). 
Many of these amplified genes are involved in cellular prolifera-
tion, survival, and angiogenesis of OS. Amplification of the 12q13 
chromosomal region (containing MDM2 and CDK4) or INK4A 
deletion at location 9p21 can affect both the p53 and pRb path-
ways, and may sometimes occur simultaneously with RB or TP53 
alterations (14). Of these amplified genes, the miRNAs targeting 
MYC and RUNX2 have been well-characterized in OS.
MYC
The MYC oncogene encodes a transcription factor that regulates 
genes that control cell growth and cell-cycle progression (52). 
Genetic and epigenetic alterations associated with constitutive 
c-Myc activation promote oncogenesis in a variety of cancers 
(52). The MYC locus is amplified in ~30% of OS tumors (53), 
and c-Myc protein is overexpressed in the majority of OS cases 
(54). Thus, dysregulation of c-Myc is an important component of 
OS pathogenesis. The c-Myc transcription factor globally silences 
several miRNAs either by inhibition of tumor suppressor miRNAs 
(including miR-15a/16-1, miR-34 family, miR-23), or activation 
of oncogenic miRNAs (e.g., miR-17–92). In addition c-Myc forms 
a feedback regulatory loop involving direct or indirect repression 
of let-7, a well-recognized tumor suppressor miRNA, through the 
RNA-binding protein, LIN28 (15, 55). Thayanithy et al. (56) dem-
onstrated significant decreases in expression levels of miRNAs at 
the 14q32 locus (miR-369-3p, miR-544, miR-134, and miR-382) 
in OS cell lines and tumors compared to normal bone tissues. 
This correlated with c-Myc overexpression and enrichment of 
the miR-17–92 cluster. In addition, miR-135b (57) and miR-33b 
(58) were demonstrated to directly repress c-Myc in OS cells 
and restoration inhibited cell proliferation, migration, and inva-
sion. Interestingly, the expression of let-7 family members was 
attenuated in OS cell lines (59, 60). This was predicted to affect 
the regulation of oncogenes that influence cell-cycle progression 
and apoptosis. Since let-7 targets multiple oncogenes including 
MYC, RAS, CCND, BCL2 (61), this miRNA may be an interesting 
candidate for future investigation in this disease.
RUNX2
The RUNX2 gene located on chromosome 6p12–p21 is frequently 
amplified in OS and is associated with tumor growth (20). This 
gene encodes a transcription factor that is necessary for both 
osteoblast differentiation and chondrocyte maturation. RUNX2 
is linked to many human cancers including breast, prostate, and 
bone cancer and also cancer metastasis in bone (62). High expres-
sion levels often correlate with poor response to chemotherapy 
(63, 64). The RUNX2 protein has been shown to directly interact 
with p53 and pRb transcription factors (58), but the precise 
function of RUNX2 in OS pathogenesis is unclear. An inverse 
correlation of expression between miR-23a and RUNX2 mRNA 
levels in OS cells and tumors was demonstrated by He et al. (65). 
An association between miR-23a and RUNX2 and chemokine 
(C–X–C motif) ligand 12 (CXCL12) mRNA was demonstrated 
as enrichment of miR-23a suppressed transcriptional activity 
of RUNX2 and inhibited proliferation in OS cells and xenograft 
tumors (65). These studies indicate a tumor suppressor function 
for miR-23a in this disease. In addition, miR-103a was reported 
to play a role in the regulation of osteoblast differentiation by 
directly targeting the 3′-UTR of RUNX2 mRNA to inhibit matrix 
mineralization and bone formation (66). Other miRNAs, miR-
135 and miR-203, were identified to modulate RUNX2 in breast 
cancer cells (67). Inhibition of RUNX2 interacting proteins by 
miRNAs also affected RUNX2 stability and transactivation poten-
tial. Protein expression levels of RUNX2 and the co-transcription 
factor, SATB2, were regulated by miR-205 and overexpression 
of the special AT-rich sequence-binding protein 2 (SATB2) 
activated RUNX2 and reversed the inhibitory effects of miR-205 
on osteoblastic differentiation (68). These studies provide more 
comprehensive details on the involvement of miRNAs involved 
in osteoblast regulation and OS.
Receptor Tyrosine Kinase Activation
Aberrant activation of RTKs and their ligands promote malignant 
progression in OS. These RTKs include epidermal growth factor 
receptor (EGFR), insulin-like growth factor 1 receptor (IGF-1R), 
vascular endothelial cell growth factor receptor (VEGFR), 
platelet-derived growth factor receptor (PDGFR), and mesen-
chymal–epithelial transition factor (c-Met). RTK activation via 
gene mutations, gene amplifications, protein overexpression, 
and/or ligand-dependent autocrine/paracrine loops has been 
demonstrated in patient primary tumors, cell lines, and xeno-
graft tumors. This is generally associated with cell proliferation, 
cell survival and metastasis, and overall poor prognosis. In the 
past decade, several monoclonal antibodies and small molecule 
inhibitors targeted against RTKs have been evaluated in pediat-
ric patients with solid tumors including OS (69). These agents 
were well-tolerated but showed limited single-agent activity in 
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patients. Moreover, resistance to these therapies due to cross-talk 
between receptors resulted in the activation of compensatory 
RTK cell survival signaling to facilitate tumor progression (15). 
A more detailed understanding of biological mechanisms of drug 
response and resistance will assist in addressing the challenges 
of RTK inhibition. Recent experimental studies have investigated 
the role of several tumor suppressor miRNAs in the regulation of 
IGF-1R and MET in OS.
IGF-1R
IGF-1R is a transmembrane receptor that is activated by IGF-1 
and IGF-2 ligands and mediates signaling involved in processes, 
such as cell proliferation, migration, and differentiation (70). 
High expression levels of IGF-1R, IGF-1, and IGF-2 have been 
demonstrated in many cancers including breast, prostate, colon, 
and pediatric cancer (71, 72). IGF-1R is overexpressed in ~45% of 
OS patients (72). In 2013, Chen et al. demonstrated that miR-16 
expression levels were low in OS cell lines and inversely correlated 
with IGF-1R mRNA levels. miR-16 is a member of the mir-15/16 
family that functions as a tumor suppressor in a variety of cancers. 
These miRNAs target BCL2 and numerous genes involved in the 
G1/S transition, such as cyclin D1 (CCND1), cyclin D3 (CCND3), 
cyclin E1 (CCNE1), and CDK6 (14). The restoration of miR-16 
in OS cells suppressed proliferation by inhibition of IGF-1R and 
the Ras/Raf/mitogen-activated protein kinase (MAPK) path-
way. These findings were significant since MAPK activation is 
associated with the induction of proliferative and anti-apoptotic 
signaling in OS (73) and in resistance mechanisms to targeted 
therapies (74). Han et al. (75) demonstrated that miR-194 directly 
targeted CDH2 and IGF-1R mRNA to suppress OS cell prolifera-
tion and metastasis in vitro and in vivo. A tumor suppressor role 
of miR-194 was also described for gastric cancer (76) and lung 
cancer (77), though bone morphogenetic protein 1 (BMP1) and 
the cyclin-dependent kinase inhibitor p27(kip1) were the targets 
of miR-194 in these cancers. Furthermore, expression of miR-
133b correlated negatively with IGF-1R, Bcl2-like 2 (Bcl2L2), 
Mcl-1, and c-Met protein levels in OS cells (78). This suggests the 
potential of miR-133b to function as a master regulator of criti-
cal genes, which control cell survival in OS. These insights into 
the miRNA-mediated regulation of IGF-1R provide new details 
of biological mechanisms of response and resistance to IGF-1R 
inhibition in preclinical models of OS.
MET
The MET oncogene encodes the receptor for the hepatocyte 
growth factor (HGF), a cytokine that stimulates invasive growth of 
normal and neoplastic cells. The c-Met receptor is overexpressed 
in a variety of human malignancies, including sarcomas, and 
particularly in chordoma (94.4%), chondrosarcoma (54.2%), and 
OS (23.3%), determined in 122 cases of malignant bone tumors 
(79). Activation of c-Met increases phosphatidylinositol-3-kinase 
(PI3K)/Akt, Src, c-Jun N-terminal kinase, signal transducer 
and activator of transcription 3 (STAT3) and MAPK pathway 
signaling, and is implicated in acquired resistance to EGFR and 
angiogenesis inhibitors (80, 81). Two miRNAs that were found 
to directly target MET mRNA in OS were miR-34a (82) and 
miR-199a-3p (83). This was consistent with previous reports that 
c-Met is one of the common targets for the miR-34 family (42). 
The overexpression of c-Met in tumors of p53-deficient mice and 
in Li–Fraumeni patients (84) suggests that miR-34/p53/c-Met 
may form a gene regulatory network that cooperatively controls 
tumor progression in OS. Restoration of either miR-34a or 
miR-199a-3p with respective miRNA mimics in OS cell lines 
achieved a reduction of cell migration and invasion. In addition, 
the repression of miR-199a-3p was associated with inhibition 
of mechanistic target of rapamycin (mTOR) as well as STAT3. 
In an independent investigation, miR-199a-3p and let-7a were 
evaluated in OS cells using lipid-modified dextran-based poly-
meric nanoparticles as a delivery system (85). Studies of effective 
delivery methods for miRNAs are relevant to achieve optimal 
miRNA enrichment or gene silencing in OS cells and tumors. 
These studies demonstrated that a lipid-modified dextran-based 
polymeric nanoparticle platform may be an effective non-viral 
carrier for efficient and effective miRNA delivery in vivo.
Cell Proliferation
The PI3K/Akt and MAPK pathways are two of the most frequently 
activated signal transduction pathways associated with OS. They 
contribute to disease initiation and development, uncontrolled 
cell proliferation, tumor cell invasion and metastasis, cell-cycle 
progression, inhibition of apoptosis, angiogenesis, and chem-
oresistance. The PI3K/Akt pathway is activated by the binding 
of ligands to respective RTKs (including IGF-1R, c-Met, and 
EGFR). Downstream signals activate targets involved in cell sur-
vival and inactivate pro-apoptotic proteins. The MAPK pathway 
is also activated by IGF-1R and EGFR signals, which may lead to 
cross-talk with the PI3K/Akt pathway. Aberrant activation of the 
MAPK pathway is often linked to lung metastasis (86) and drug 
resistance in OS (74). The influence of miRNAs on components 
of these pathways has been studied in OS pathology.
PI3K/Akt
The PTEN protein functions as a tumor suppressor that negatively 
regulates activation of the Akt pathway to inhibit cell prolifera-
tion (87). Gene deletions at the PTEN locus account for loss of 
PTEN function in 15–33% of OS patients (88). Consequently, loss 
of PTEN is associated with tumor progression. PTEN mRNA was 
directly targeted by miR-221 in OS cell lines and high miR-221 
levels were shown to correlate with low PTEN mRNA and protein 
expression (89). Enrichment with miR-221 mimics induced OS 
cell survival while attenuation with antimiRs induced apoptosis, 
demonstrating that this is an oncogenic miRNA in OS. Notably, 
inhibition of miR-221 enhanced sensitivity to cisplatin (89), 
indicating the involvement of miR-221 in drug resistance mecha-
nisms. Other miRNAs including miR-92a and members of the 
miR-17 and miR-130/301 families were found to show an inverse 
correlation in expression levels with PTEN mRNA expression 
levels in OS tumors (37) to provide additional candidates for 
investigation. Of these, inhibition of miR-17 resulted in increased 
PTEN mRNA in OS, which was associated with suppression of 
tumor growth and metastasis (90).
Another critical component in the PI3K/Akt pathway is the 
mTOR protein kinase. The mTOR complex consists of mTOR 
complex-1 (mTORC1), which regulates cellular proliferation, 
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and mTOR complex-2 (mTORC2), which phosphorylates and 
activates Akt. Direct repression of mTOR by the miR-101 tumor 
suppressor was reported in OS (91), and inhibition of cell pro-
liferation and apoptosis were mediated through suppression of 
mTOR. Growth inhibition by miR-101 was also shown in hepa-
tocellular carcinoma cells (92), and miR-101 was also found to 
contribute to cisplatin-induced apoptosis. Thus, these miR-221/
miR-17/PTEN and miR-101/mTOR interactions provide new 
insight into the role of miRNAs as potential regulators of aberrant 
PI3K/Akt pathway signaling in OS. Further, the identification of 
miRNAs associated with resistance to cisplatin is promising for 
the development of biomarkers of chemoresistance in this disease.
MAPK
Epidermal growth factor receptor signaling with activation of 
the MAPK pathway occurs in 49% of OS cases and is linked 
to metastatic disease (93). Ras/Raf is upstream of MAPK/ERK 
kinase (MEK). Aberrant activation of the Ras/Raf/MAPK path-
way is known to be specifically associated with OS initiation, 
progression, and outcome. A direct interaction between miR-217 
and KRas was recently reported to participate in MAPK activa-
tion in OS (94). In a study evaluating miR-143 in OS tumors, 
a direct association of elevated EGFR phosphorylation and 
matrix metalloprotease-9 (MMP-9) levels and low miR-143 
expression was reported (95). The MMP family of proteolytic 
enzymes facilitates tumor cell invasion and metastasis through 
degradation of various components of the extracellular matrix 
(96). MMP-9 degrades collagen type IV, the major component of 
the basement membrane and overexpression is associated with 
tumor metastasis (96). In this study, EGF promoted activation of 
EGFR and induced MMP-9 to enhance the ability of OS cells to 
metastasize. Significantly, miR-143 was reported to inhibit EGFR 
signaling-dependent OS cell invasion.
Apoptosis
Apoptosis is a critical event in embryonic development and in 
maintenance of tissue homeostasis of multicellular organisms. 
The activation of anti-apoptotic signals facilitates uncontrolled 
cell growth in cancer cells. The major apoptotic pathways include 
both the intrinsic and extrinsic pathways. The intrinsic pathway is 
mediated by mitochondrial components and triggered by intracel-
lular stimuli, such as DNA damage, cytotoxic agents, growth fac-
tor suppression, and/or oxidative stress. The extrinsic pathway is 
initiated by the binding of death ligands, Fas ligand (FasL), tumor 
necrosis factor (TNF), TNF-related apoptosis-inducing ligand 
(TRAIL), and TNF-like weak inducer of apoptosis (TWEAK) to 
the TNF receptor (TNFR) superfamily of death receptors (97). 
Other key proteins in tumor cells that control apoptosis include 
the tumor suppressor p53 and PI3K/Akt activation that regulate 
downstream substrates that trigger or prevent apoptosis, respec-
tively (97). miRNAs directly targeting components of the basic 
apoptotic pathways in OS have been identified.
Intrinsic Apoptotic Pathway
Low levels of miR-133a in OS cell lines and tissues were found 
to correlate with tumor progression and poor prognosis (98). 
Restoration of miR-133a inhibited cell proliferation and induced 
apoptosis in OS cell lines. A similar tumor suppressor role for 
miR-133a was reported in colorectal cancer (99). The regulatory 
mechanism of miR-133a involved direct targeting and sup-
pression of B-cell lymphoma-extra large (Bcl-xL) and Mcl-1 
proteins. Both Bcl-xL and Mcl-1 are anti-apoptotic proteins 
that are highly expressed in OS and promote cell survival (100). 
The miR-29 family comprises three isoforms arranged in two 
clusters, miR-29b-1/miR-29a located on chromosome 7 and 
miR-29b-2/miR-29c on chromosome 1, and these miRNAs 
have been identified as tumor suppressors in chronic lymphatic 
leukemia (CLL), AML, lung cancer, and breast cancer (101). Low 
levels of miR-29a were observed in OS, which when restored, 
induced apoptosis leading to the silencing of BCL2 and MCL1 
and enrichment of the tumor suppressors E2F1 and E2F3 (35). 
miR-29 is currently being clinically evaluated as a biomarker 
for primary measure outcome of histone deacetylase inhibitor, 
AR-42, in adult and pediatric AML patients (NCT01798901). A 
clinical trial to evaluate the molecular mechanism and clinical 
significance of the interaction between Twist1 and other epithe-
lial-to-mesenchymal regulators through the miR-29 family is 
also underway (NCT01927354). Another study investigating the 
role of miR-29b in patients with oral squamous cell carcinoma 
has been proposed (NCT02009852). Collectively, these data 
support a tumor suppressor function of miR-29 and suggest that 
the use of synthetic miR-29 oligonucleotides or agents increasing 
miR-29 expression can be incorporated in the study of expres-
sion changes of critical genes in OS.
Extrinsic Apoptotic Pathway
Fas ligand (FasL or CD95L) is a type-II transmembrane protein 
that belongs to the TNF family (97). FasL binds the Fas receptor 
(Fas, also called apoptosis antigen 1, Apo1, or cluster of differ-
entiation 95, CD95) and induces apoptosis. Low Fas expression 
in OS tumor cells was associated with disease development and 
progression. Huang et  al. demonstrated that miR-20a encoded 
by the miR-17–92 cluster attenuated FAS levels and regulated 
Fas-mediated apoptosis in OS cells (102). Another miRNA, 
miR-106a, which was downregulated in OS cell lines and tumors, 
was associated with regulation of FAS (103). miR-106a is part of 
a miRNA cluster (miR-17, miR-18a, miR-92a, and miR-106b), 
and cross-talk between miRNAs was suggested to mediate FAS 
repression. Interestingly, the pro-apoptotic gene BH3-only (BIM) 
was suppressed by miR-17 only (103) to support the regulation of 
Fas-mediated apoptosis by this miRNA cluster in OS cells.
Metastasis
In general, OS patients with lung metastasis have a poor progno-
sis. The overall survival rate is low (~25%) for those patients who 
present with metastases (~20% of all cases) (104). The process 
of metastasis involves dissemination of cells from the primary 
tumor, invasion of the extracellular matrix, and proliferation of 
cells at distant sites (105). A number of factors, including Rho-
associated coiled-coil kinase 1 (ROCK1), MMPs, and c-Fos (the 
cellular homolog of v-fos), are involved in tumor metastasis. 
Recent studies have identified several miRNAs that directly 
target the mRNAs encoding these proteins. The identification 
of miRNAs associated with metastatic disease holds promise as 
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circulating miRNA biomarkers assessing disease characteristics 
that may be detected in serum and plasma of patients.
Rho-Associated Coiled-Coil Kinase 1
The ROCK1 protein serine/threonine kinase is a downstream 
effector of the small GTPase RhoA, and is a regulator of the 
actomyosin cytoskeleton. The RhoA/ROCK pathway participates 
in the process of tumorigenesis in numerous types of cancer. 
ROCK1 promotes contractile force generation and is involved in 
cell motility, metastasis, and angiogenesis in cancer cells (106). 
Several miRNA:ROCK1 mRNA associations have been described. 
Generally, ROCK1-associated miRNAs, miR-340 (107), miR-335 
(108), miR-145 (109), and miR-144 (110), were weakly expressed 
in OS cell lines and tissues and correlated inversely to ROCK1 
overexpression. In addition, low expression levels of these miR-
NAs were associated with OS progression and metastasis through 
mechanisms involving ROCK1 to provide initial evidence that 
supports these miRNAs as predictors of poor prognosis in OS.
MMP-13
Matrix metalloproteases are produced either by tumor cells or 
stromal cells. Overexpression of MMP proteins is an impor-
tant predictive factor for relapse or nodal metastasis of many 
carcinomas (111, 112). MMP-13 expression is common in lung 
metastasis (31). Recent evidence shows the emerging roles 
of miRNAs in direct repression of MMP through inhibition 
of gene transcription or (113) inhibition of MMP RNA levels 
(114). Osaki et al. showed that the expression of miR-143 was 
significantly downregulated in comparison to expression levels 
in parental (HOS) cell line and subclone (143B) human OS cell 
line, which shows lung metastasis in a mouse model (31). This 
finding correlated with MMP-13 upregulation, which implicated 
MMP-13 as a downstream mediator of miR-143 function in OS 
metastasis.
FOS
FBJ murine osteosarcoma viral oncogene homolog (FOS) is 
the transforming gene identified originally in the FBi and FBR 
murine sarcoma viruses (115). The c-Fos protein is part of a 
heterodimeric complex with JUN and is a major component 
of the Activator Protein-1 (AP-1) transcription factor complex. 
AP-1 regulates cell growth, differentiation, transformation, and 
bone metabolism (116). c-Fos is overexpressed in 61% of OS 
tumors compared to benign and normal tissue (117). It is also 
enriched in high-grade lesions and in patients with metastases 
(42%). c-Fos overexpression in transgenic mice was associated 
with OS development, suggesting a potential role in tumor initia-
tion (118). The correlation between low expression of miR-181b/
miR-21 signaling and FOS upregulation was made in malignant 
gliomas (119). miR-181b modulated FOS expression by directly 
targeting the binding site within the 3′-UTR. mir-221 was a pre-
dicted gene target of FOS (10), but the integrated analyses of FOS 
mRNA and regulatory miRNAs have not been experimentally 
studied in OS.
Drug-Resistant Genes
Drug resistance is often mediated through the activation of 
several molecular pathways that inhibit apoptosis and promote 
cell survival, to compensate for the effects of chemotherapy and 
targeted inhibition. In addition, increased DNA damage repair 
and ejection of the drug from the cell by drug efflux pumps reduce 
the efficacy of many cytotoxic agents. Experimental studies have 
demonstrated that the altered expression of specific miRNAs that 
regulate these cellular processes leads to drug resistance in differ-
ent cancers. In OS cells, overexpression of miR-221 and miR-101 
caused cisplatin resistance, mediated through the PTEN/Akt 
pathway (89, 92), while conversely, increased miR-217 expression 
levels were associated with reduction in KRas and enhanced sen-
sitivity to quercetin and/or cisplatin (50). In the study conducted 
by Song et al., miR-215 was shown to induce G2 arrest in OS and 
colon cancer cells leading to chemoresistance to methotrexate 
and Tomudex (50).
MDR1
An underlying cause of multi-drug resistance (MDR) in OS is the 
overexpression of one or more of the ATP-binding cassette (ABC) 
transporters. Many cytotoxic agents are substrates for the MDR1 
(ABCB1) gene, resulting in overexpression of P-glycoprotein 
(P-gp), a 170–190 kDa transmembrane glycoprotein that belongs 
to the ABC superfamily (120). MDR (in particular, ABCB1, 
ABCG2, and ABCC family members) mediates the efflux of many 
cytotoxic agents in OS to decrease drug efficacy (120). Zhu et al. 
(121) have demonstrated that MDR1/P-gp expression in human 
cancer cells was regulated by high levels of miR-27a and miR-451 
expression. miR-27a/miR-27a* is a miRNA pair derived from a 
single precursor. In this study, the sensitivity to and intracellular 
accumulation of cytotoxic drugs that were transported by P-gp 
were enhanced by treatment with antagomirs against miR-27a, 
demonstrating a role in MDR1-mediated chemoresistance in OS. 
miR-27a/miR-27a* was also shown to promote pulmonary OS 
metastases formation (122) to suggest this miRNA functions as 
an oncogene in this disease. In contrast, in head and neck squa-
mous cell carcinoma, miR-27a* was demonstrated as a tumor 
suppressor by targeting the EGFR signaling axis (123) to illustrate 
fundamental differences in miRNA expression between OS and 
other types of cancer.
Challenges and Future Perspectives
Recent studies have generated a vast amount of DNA sequenc-
ing and genomic data that have provided tremendous insight 
into the molecular pathology of OS (4). Several genetic and 
epigenetic alterations in OS have been established that are 
linked to the development, proliferation, and survival of tumor 
cells (17, 19). The mapping of human miRNA genes has also 
identified specific miRNAs in OS that modulate gene expression 
and cellular processes. This has provided new insight into the 
complex genetic mechanisms of OS tumorigenesis. Many of 
these miRNA genes are located in cancer-associated genomic 
regions or in fragile sites (8, 18) and are reportedly associated 
with the development, progression, and metastasis of OS tumors 
(represented in Figure 1 and summarized in Table 1). miRNAs 
are intriguing molecules, as the expression patterns appear to be 
tissue and cancer-type specific, and the small size is amenable 
to development for clinical applications. Of interest, circulat-
ing miRNAs from tumor cells that are detected in the blood of 
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patients with cancer present a novel opportunity to use miRNAs 
as an early predictor of cancer as well as a marker of response 
to therapy.
Research characterizing distinct OS-associated miRNAs is 
still in its infancy. The dysregulation of miRNAs in OS is likely 
influenced by a variety of factors, which are only starting to 
be understood. Since OS is a disease that is marked by genetic 
abnormalities including mutations, single-nucleotide poly-
morphisms (SNPs), and gene amplifications, it is expected that 
these alterations may also affect miRNA function. Mutations 
in the miRNA recognition sites of target mRNAs may affect 
miRNA binding, resulting in escape from regulation by a 
specific miRNA. Gene mutations and sequence variation muta-
tions affecting miRNA sequences can potentially affect either 
processing and/or expression of mature miRNAs to prevent 
recognition of mRNA targets. However, at present, there is no 
clear association between mutations and SNPs identified in 
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FiGURe 1 | Network of miRNAs and target genes in OS. The figure depicts 
altered miRNA genes that play a critical role in the development and progression 
of OS. The majority of miRNAs are downregulated (tumor suppressors) and target 
genes are overexpressed (oncogenes). Upregulated miRNAs (oncogenes) are 
depicted by upward arrows and target genes are repressed (tumor suppressors). 
Abbreviations: MDR1, multi-drug resistance 1; FasL, Fas ligand; IGF-1R, 
insulin-like growth factor 1 receptor; EGFR, epidermal growth factor receptor; 
ROCK1, Rho-associated coiled-coil kinase 1; Bcl2, B-cell lymphoma-2; Bcl-xL, 
B-cell lymphoma-extra large; Mcl-1, myeloid leukemia cell differentiation protein; 
PTEN, phosphatase and tensin homolog; MMP-13, matrix metalloprotease-13; 
N-Cad, N-Cadherin; SATB2, special AT-rich sequence-binding protein 2; RUNX2, 
runt-related transcription factor 2; DTL, denticleless protein homolog). Solid gray 
arrows represent activated signaling pathway; solid blunt lines represent inhibition 
of signals; dotted gray lines represent indirect signaling pathways.
miRNA precursors in tumors, and cancer cell lines. These are 
not generally attributed to tumorigenesis and do not alter the 
secondary structure or function of the mature miRNAs (125, 
126). Only few studies of this type have been conducted in OS 
specifically. Further screening for genetic variants in miRNA 
genes warrants investigation to determine whether genetic 
aberrations in miRNAs are integrated into the known cytoge-
netic abnormalities observed in OS.
Many of the miRNAs discussed in this review are preliminary 
findings based on in vitro studies using cell lines derived from OS 
tumors and are not fully validated in vivo or in functional studies. 
The robust confirmation of individual or miRNA signatures in 
preclinical disease models is important for potential applications 
to cancer treatment. Reduced levels of mature miRNAs in tumors 
may be a consequence of true absence (lack of inheritance), 
secondary loss (genetic loss, epigenetic silencing), or defects in 
biogenesis pathways or transcriptional repression. Quantitative 
TABLe 1 | Prominent clinopathological factors associated with OS and regulatory miRNAs that are validated in preclinical OS models.
OS-associated factor Target gene/pathway miRNA Altered protein(s) miRNA function Reference
Germline mutation RB1 miR-17–92 Not verified in OS Oncogene (36, 37)
TP53 miR-34 p53 aTS (45)
bmiR-192 p53/RUNX2 TS (46)
bmiR-215 p53 TS (48)
Gene amplification MYC bmiR-369-3p c-Myc TS (56)
bmiR-544
bmiR-134
bmiR-382
miR-135b c-Myc TS (57)
miR-33b c-Myc TS (58)
RUNX2 miR-23a RUNX2/CXCL12 TS (65)
miR-205 RUNX2/SATB2 (66)
Receptor tyrosine kinase 
activation
IGF-1R miR-16 IGF-1R TS (124)
MET miR-194 IGF-1R/N-Cadherin TS (75)
miR-133b IGF-1R/Bcl2L2/Mcl-1/c-Met TS (78)
miR-34 c-Met TS (82)
miR-199a-3p c-Met TS (83)
Cell proliferation PI3K/Akt miR-221 PTEN Oncogene (89)
miR-17 PTEN Oncogene (37)
MAPK miR-143 pEGFR TS (95)
Apoptosis Intrinsic pathway miR-133a Bcl-xL/Mcl-1 TS (100)
miR-29 Bcl2/Mcl-1/MMP TS (35)
Extrinsic pathway miR-20a FasL TS (102)
miR-106a FasL TS (103)
miR-17 BIM TS (103)
Metastasis ROCK1 miR-340 ROCK1 TS (107)
miR-335 ROCK1 TS (108)
MMP-13 miR-145 ROCK1 TS (109)
miR-144 ROCK1 TS (110)
FAS miR-143 MMP-13 TS (31)
miR-20a FasL TS (102)
Drug resistance MDR1 miR-27a P-gp Oncogene (121)
aTS, tumor suppressor.
bmiRNA signature.
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real-time reverse transcription polymerase chain reaction (qRT-
PCR) and oligonucleotide microarray (microchip) analysis are 
the most common methods for measuring miRNA levels, but 
there is currently no standardized technique for evaluation of 
miRNA expression, which is critical for clinical translation. In 
addition, miRNA potential targets can be predicted using compu-
tational algorithms, such as TargetScan (127) and microRNA.org 
(128). By computer predictions and stable isotope labeling with 
amino acids in cell culture (SILAC), a single miRNA has multiple 
targets and is capable of inhibiting the translation of hundreds 
of proteins (129). These are valuable tools for the integrated and 
functional analyses of miRNA and mRNA targets, and miRNA 
gene networks, which are also essential for understanding global 
miRNA roles in OS tumors.
Importantly, miRNA targets are tissue specific and the regula-
tory roles are in particular physiological or pathological contexts. 
Approximately 60% of mRNAs have evolutionarily conserved 
sequences that are predicted to bind miRNAs (130). Thus, the 
expression of target genes may be controlled by several different 
miRNAs, and cross-talk between miRNA networks may affect 
an individual miRNA-based effect. Consequently, an individual 
miRNA may have oncogenic or tumor suppressor properties in 
different cell types. Finally, further research to develop strategies 
for effective and safe miRNA delivery systems is needed. Localized 
delivery or the use of polyethylene glycol (PEG) in PEGylated 
liposomes, lipidoids, and biodegradable polymers are being tested 
[reviewed in Ref. (131)]. Improvements in delivery formulations 
will reduce the risk of hepatotoxicity, organ failure, and death in 
preclinical mouse models (131). The design of miRNA precursor 
mimics (e.g., short hairpin RNAs) or true pre-miRNAs may also 
minimize toxic side effects while retaining targeted functions. 
Nonetheless, these small molecules have greatly enhanced our 
knowledge of the molecular mechanisms that regulate gene 
expression in OS, and it is hoped miRNAs will be successfully 
developed to improve the current management of OS.
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